- Digital Approach to Weight Loss: Slimming Injections Accelerated Through Weight-Loss Apps
- App-Enabled Prescription: Specialized Weight Management Services Embrace Four Approved Apps
- Medication and Its Effects: Semaglutide-Based Treatments Revolutionize Obesity Fight, With Side Effects
Overweight Britons will be encouraged to download weight-loss applications to receive their slimming injections more quickly.
Wegovy, Ozempic, and Saxenda are available only through specialized clinics.
However, according to health officials, doctors are “unable to keep up with demand,” and patients are in dire need of a remedy, as the medication is a crucial weapon in the fight against obesity.
Thousands of people referred to weight management services can now skip long wait times for in-person care.
The National Institute for Health and Care Excellence (NICE) has authorized four apps to prescribe vaccinations.
Liva, Oviva, Roczen, and Second Nature, which also encourage patients to consume healthier and exercise more, can be downloaded from a computer or mobile app.
The NHS watchdog NICE forecasts that 48,000 people will use the services, saving 145,000 clinician hours.
Wegovy, Ozempic, and Saxenda’s strong semaglutide and liraglutide have transformed obesity treatment.
The medications mimic GLP-1, which the gut releases after eating, to help you lose weight.
In addition to instructing the pancreas to produce more insulin, the GLP-1 hormone flows back to the brain and induces satiety.
However, these medications do have adverse effects.
After taking the medication, vertigo, constipation, and diarrhea are common complaints.
In 2021, Wegovy was authorized as a drug for weight loss in the United States.
This year, it was approved in the United Kingdom for the same reason.
Novo Nordisk, the drug’s producer, is stockpiling before UK distribution due to increased demand.
Ozempic, the alternative brand-name version of semaglutide, is restricted to individuals with type 2 diabetes.
Experts estimate that 70% of people lack local weight management services due to uneven distribution.
In response to the current proposal, the Secretary of health, Steve Barclay, stated that “technology is transforming healthcare.”
The use of apps in weight management services will increase access to support that, along with life-changing medications, can help combat obesity, which costs the NHS billions annually and is the second leading cause of cancer.
The latest obesity medications have the potential to help patients lose significant quantities of weight and reduce related conditions, but they must be used in conjunction with diet, physical activity, and broader behavioral support to prevent weight regain.
Mark Chapman, interim director of medical technology and digital evaluation at Nice, stated, ‘Traditional face-to-face services for treating individuals with obesity cannot keep up with demand.
‘Waiting lists are lengthy, some locations lack a service, and patients require a remedy.
